Immunocore Holdings plc IMCR
27.57 USD +0.05 (+0.20%)
As ofNov 19, 2026, 10:15 AM EST
27.25 Day range 28.29
27.25 52-week range 40.72
- YTD
- -20.58%
- 1 year
- -28.68%
News
seekingalpha.com Immunocore Holdings plc (IMCR) Presents at UBS Global Biopharma Conference 2026 Transcript Immunocore Holdings plc (IMCR) Presents at UBS Global Biopharma Conference 2026 Transcriptbenzinga.com Morgan Stanley Maintains Equal-Weight on Immunocore Holdings, Lowers Price Target to $42 Morgan Stanley analyst Sean Laaman maintains Immunocore Holdings (NASDAQ:IMCR) with a Equal-Weight and lowers the price target from $43 to $42.
benzinga.com HC Wainwright & Co. Maintains Buy on Immunocore Holdings, Lowers Price Target to $80 HC Wainwright & Co. analyst Patrick R. Trucchio maintains Immunocore Holdings (NASDAQ:IMCR) with a Buy and lowers the price target from $100 to $80.
benzinga.com Immunocore Holdings Announces Data Form Its Phase 1/2 Study Of Brenetafusp Shows 29% Overall Response Rate, 71% Disease Control Rate Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve
benzinga.com Immunocore Hldgs Q3 EPS $(0.28) Misses $(0.10) Estimate, Sales $102.222M Miss $113.438M Estimate Immunocore Hldgs (NASDAQ:IMCR) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.10) by 180 percent. The company reported quarterly sales of $102.222…
benzinga.com Immunocore To Present Phase 1/2 Trial Data Evaluating Brenetafusp Alone And In Combination With KIMMTRAK In HLA-A*02:01-Positive Patients With Metastatic Uveal Melanoma, At 2026 SITC Annual Meeting Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meetingClinical data for…
benzinga.com HC Wainwright & Co. Reiterates Buy on Immunocore Holdings, Maintains $100 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Immunocore Holdings (NASDAQ:IMCR) with a Buy and maintains $100 price target.
